FDA issued approval letters for two novel agents in the last week: Lexicon Pharmaceuticals Inc.'s Xermelo and ALK-Abello AS's Odactra.
Odactra, a sublingual house dust mite allergen extract, is the first novel biologic to come out of the Center for...





